BR112022019846A2 - Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos - Google Patents
Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostosInfo
- Publication number
- BR112022019846A2 BR112022019846A2 BR112022019846A BR112022019846A BR112022019846A2 BR 112022019846 A2 BR112022019846 A2 BR 112022019846A2 BR 112022019846 A BR112022019846 A BR 112022019846A BR 112022019846 A BR112022019846 A BR 112022019846A BR 112022019846 A2 BR112022019846 A2 BR 112022019846A2
- Authority
- BR
- Brazil
- Prior art keywords
- ccdp12
- rms
- methods
- reduce
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019846A2 true BR112022019846A2 (pt) | 2022-11-22 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019846A BR112022019846A2 (pt) | 2020-04-03 | 2021-04-01 | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (https=) |
| EP (1) | EP4125906A1 (https=) |
| JP (1) | JP2023520469A (https=) |
| KR (1) | KR20220163986A (https=) |
| CN (1) | CN115916205A (https=) |
| AU (1) | AU2021249129A1 (https=) |
| BR (1) | BR112022019846A2 (https=) |
| CA (1) | CA3177390A1 (https=) |
| CL (1) | CL2022002699A1 (https=) |
| IL (1) | IL296990A (https=) |
| MX (1) | MX2022012310A (https=) |
| TW (1) | TWI907406B (https=) |
| WO (1) | WO2021202825A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173740A1 (en) * | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2022240920A1 (en) | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| TW202508592A (zh) * | 2023-05-16 | 2025-03-01 | 美商建南德克公司 | 使用布魯頓酪胺酸激酶之抑制劑來治療復發型多發性硬化症之方法 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| KR20170033358A (ko) | 2014-08-07 | 2017-03-24 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나아제 저해제의 신규한 제제 |
| WO2017148837A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| KR102635949B1 (ko) | 2017-05-18 | 2024-02-14 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도 |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| EP3849559A4 (en) * | 2018-09-12 | 2022-06-01 | Denovo Biopharma LLC | COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF |
| TW202042815A (zh) | 2019-01-22 | 2020-12-01 | 美商建南德克公司 | 使用布魯頓（bruton）酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法 |
| WO2021173740A1 (en) | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
-
2021
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4125906A1 (en) | 2023-02-08 |
| TW202203925A (zh) | 2022-02-01 |
| CA3177390A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| AU2021249129A1 (en) | 2022-10-20 |
| CN115916205A (zh) | 2023-04-04 |
| WO2021202825A1 (en) | 2021-10-07 |
| CL2022002699A1 (es) | 2023-03-31 |
| JP2023520469A (ja) | 2023-05-17 |
| IL296990A (en) | 2022-12-01 |
| TWI907406B (zh) | 2025-12-11 |
| MX2022012310A (es) | 2022-10-27 |
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019846A2 (pt) | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos | |
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| BR112018072339A2 (pt) | tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| EP4349360A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| EA201992658A1 (ru) | Методы лечения рекуррентной глиобластомы (rgbm) | |
| PH12020551076A1 (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| PH12021553102A1 (en) | Methods of treating fabry disease in patients having renal impairment | |
| JOP20230276A1 (ar) | تركيبات وطرق لعلاج الاكتئاب | |
| Svensson et al. | Endogenous dopaminergic modulation of the lamprey spinal locomotor network | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| MX2022004056A (es) | Composicion novedosa para el cuidado de la piel. | |
| Zhang et al. | Noval advance of histone modification in inflammatory skin diseases and related treatment methods | |
| ZA202103914B (en) | Cxcr7 inhibitors for the treatment of cancer | |
| BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
| BRPI0716929A8 (pt) | tratamento de esclerose múltipla com campath-1h | |
| MX2022004055A (es) | Composicion novedosa para el cuidado de la piel. | |
| MX2022004050A (es) | Composicion novedosa para el cuidado de la piel. | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| WO2020005869A3 (en) | Compositions and methods for the treatment of cancer characterized with pcsk9 expression |